Sugi Predict

Sugi Predict / Compounds / SCHEMBL15919266

SCHEMBL15919266

SCHEMBL15919266

CC(C)(C)OC(=O)NCCOc1ccc(B2OC(C)(C)C(C)(C)O2)cc1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 2/20 0.61
▸ CA1 P00915 6/20 0.57
▸ CA2 P00918 6/20 0.57
▸ CA9 Q16790 6/20 0.57
▸ CA12 O43570 5/20 0.57
▸ PRMT5 O14744 1/20 0.49
▸ WDR77 Q9BQA1 1/20 0.49
▸ PDK2 Q15119 1/20 0.47
▸ HIF1A Q16665 3/20 0.44
▸ BCHE P06276 1/20 0.43
▸ CNR2 P34972 1/20 0.43
▸ ITGB3 P05106 1/20 0.43
▸ ITGA2B P08514 1/20 0.43
▸ DGAT1 O75907 1/20 0.42
▸ SUCNR1 Q9BXA5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16493221 0.96 AAK1 (0.60) AAK1CA1CA2CA9CA12
SCHEMBL15481247 0.94 AAK1 (0.55) AAK1CA1CA2CA9CA12
SCHEMBL20317434 0.93 AAK1 (0.57) AAK1CA1CA2CA9CA12
SCHEMBL2151494 0.93 AAK1 (0.59) AAK1CA1CA2CA9CA12
SCHEMBL16014145 0.86 PDK2 (0.49) AAK1CA1CA2CA9CA12
SCHEMBL26000464 0.85 AAK1 (0.53) AAK1CA1CA2CA9CA12
SCHEMBL15036808 0.85 CA12 (0.49) AAK1CA1CA2CA9CA12
SCHEMBL18530350 0.84 DGAT1 (0.60) AAK1CA1CA2CA9CA12
SCHEMBL20911811 0.84 AAK1 (0.64) AAK1CA1CA2CA9CA12
SCHEMBL22816055 0.84 MTNR1A (0.58) AAK1CA1CA2CA9PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025106939-A1 CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF Praxis Biotech LLC (US) 2025-05-22 — — WO disclosed
US-20240408218-A1 CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS Københavns Universitet (DK) 2024-12-12 — — US disclosed
EP-4408475-A1 CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS Københavns Universitet (DK) 2024-08-07 — — EP disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 — — US disclosed
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 — — US disclosed
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 — — US disclosed
WO-2023153504-A1 NUCLEIC ACID DELIVERY MATERIAL 国立大学法人東海国立大学機構 2023-08-17 — — WO disclosed
US-20230117831-A1 MULTI-FUNCTIONAL CHIMERIC MOLECULES THE BROAD INSTITUTE, INC. 2023-04-20 — — US disclosed
WO-2023052415-A1 CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS Københavns Universitet (DK) 2023-04-06 — — WO disclosed
WO-2023052415-A1 CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS Københavns Universitet (DK) 2023-04-06 — — WO disclosed
US-20160000760-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 — — US disclosed
US-20160000760-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 — — US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 — — US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 — — US disclosed
US-9187489-B2 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-11-17 — — US disclosed
US-9187489-B2 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-11-17 — — US disclosed
EP-2857404-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR Daiichi Sankyo Co., Ltd. (JP) 2015-04-08 — — EP disclosed
US-20150051190-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-02-19 — — US disclosed
US-20150051190-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-02-19 — — US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO AAK1 1410/4885CA1 356/4885CA2 209/4885
US-20150051190-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS ROS1, JAK1, ERBB2 AAK1 258/4885CA1 4170/4885CA2 958/4885
US-20230117831-A1 MULTI-FUNCTIONAL CHIMERIC MOLECULES PHAX, PAICS, SARS1 AAK1 2541/4885CA1 4352/4885CA2 4730/4885
US-20240408218-A1 CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS GLP1R, PRKAG1, GCGR AAK1 272/4885CA1 3302/4885CA2 2997/4885
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA AAK1 661/4885CA1 4161/4885CA2 856/4885
US-20160000760-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS AAK1 3579/4885CA1 4813/4885CA2 4793/4885
US-11795169-B2 MAP4K4 inhibitors MAP4K4, MAP4K2, MAP4K5 AAK1 239/4885CA1 4427/4885CA2 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.